[1] Jennings, C. H. (2009). Nanotechnology in the USA: Developments, Policies and Issues. Nova Science Publishers, Incorporated.
[2] Trgovcević, Z. (1994). 50 years of molecular biology. Lijecnicki vjesnik, 116(11-12), 315-318.
[3] Lewin R. (1987). National Academy looks at human genome. Science, Feb13; 235 (4790). 747-8.
[4] Johnson, R. S. (1987). The human genome project: what impact on basic research?. The FASEB Journal, 1(6), 502-505.
[5] Yang, Z. R., & Hamer, R. (2007). Bio-basis function neural networks in protein data mining. Current pharmaceutical design, 13(14), 1403-1413.
[6] Ahrens, C. H., Wagner, U., Rehrauer, H. K., Türker, C., & Schlapbach, R. (2007). Current challenges and approaches for the synergistic use of systems biology data in the scientific community. In Plant Systems Biology. Birkhäuser Basel, 277-307.
[7] Ordan, B. R. (1999). ‘Genomics’: Buzzword or reality? Journal of biomedical science, 6(3), 145-150.
[8] Weyant, R. G. (1967). Lycurgus: The father of applied psychology? American Psychologist, 22(6), 432.
[9] Tolochko, N. K. (2009). History of nanotechnology. Encyclopedia of Life Support Systems (EOLSS).
[10] Logothetidis, S. (Ed.). (2012). Nanomedicine and nanobiotechnology. Springer Science & Business Media.
[11] Bawa, R., Audette, G. F., & Rubinstein, I. (2016). Handbook of clinical nanomedicine: nanoparticles, imaging, therapy, and clinical applications. Pan Stanford.
[12] Hulla, J. E., Sahu, S. C., & Hayes, A. W. (2015). Nanotechnology: History and future. Human & experimental toxicology, 34(12), 1318-1321.
[13] Jain, K. K. (2004). Applications of biochips: from diagnostics to personalized medicine. Current opinion in drug discovery & development, 7(3), 285-289.
[14] Brown, E. M. B. (2014). Nanomedicine Advancements in Cancer Diagnosis and Treatment. Horizons in Clinical Nanomedicine, 67.
[15] Emerich DF. (2005). Nanomedicine-prospective therapeutic and diagnostic applied usages. Expert Opin. Biol. Ther, Jan;5(1). 1-5.
[16] Avti, P. K., Patel, S. C., & Sitharaman, B. (2011). Nanobiomaterials: current status and future prospects. Nanobiomaterials handbook Edited by Balaji Sitharaman. CRC publication.
[17] Lee, L. A., & Wang, Q. (2006). Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomedicine: Nanotechnology, Biology and Medicine, 2(3), 137-149.
[18] Murthy, S. K. (2007). Nanoparticles in modern medicine: state of the art and future challenges. International journal of nanomedicine, 2(2), 129-41.
[19] Pauwels, E. K., & Erba, P. (2007). Towards the use of nanoparticles in cancer therapy and imaging. Drug news & perspectives, 20(4), 213-220.
[20] Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005). Nanomedicine: current status and future prospects. The FASEB journal, 19(3), 311-330.
[21] Gulati, N., & Gupta, H. (2012). Nanomedicine: Potential devices for diagnostics. Recent Patents on Nanomedicine, 2(2), 146-155.
[22] Nakayama, M., & Okano, T. (2005). Drug delivery systems using nano-sized drug carriers. Gan to kagaku ryoho. Cancer & chemotherapy, 32(7), 935-940.
[23] Dutta, R. C. (2007). Drug carriers in pharmaceutical design: promises and progress. Current pharmaceutical design, 13(7), 761-769.
[24] Dobson, J. (2006). Magnetic micro-and nano-particle-based targeting for drug and gene delivery. Nanomedicine.
[25] Freitas, R. A. (2005). Nanotechnology, nanomedicine and nanosurgery. International Journal of Surgery, 4(3), 243-246.
[26] Ebbesen, M., & Jensen, T. G. (2006). Nanomedicine: techniques, potentials, and ethical implications. BioMed Research International, 2006.
[27] Fankhauser, F., Niederer, P. F., Kwasniewska, S., & van der Zypen, E. (2004). Supernormal vision, high-resolution retinal imaging, multiphoton imaging and nanosurgery of the cornea–a review. Technology and Health Care, 12(6), 443-453.
[28] Lamounier, J. A., Moulin, Z. S., & Xavier, C. C. (2004). Recommendations for breastfeeding during maternal infections. Jornal de pediatria, 80(5), s181-s188.
[29] Iwaki, Y., Aiba, N., Tran, H. T. T., Ding, X., Hayashi, S., Arakawa, Y., & Abe, K. (2003). Simian TT virus (s-TTV) infection in patients with liver diseases. Hepatology research, 25(2), 135-142.
[30] Pawłowska, M., & Halota, W. (2004). HCV infections in view of clinical practice. Medical Science Monitor, 10(1), 24-28.
[31] Filteau, S. M. (2000). Role of breast-feeding in managing malnutrition and infectious disease. Proceedings of the Nutrition Society, 59(4), 565-572.
[32] Lawrence, R. M., & Lawrence, R. A. (2004). Breast milk and infection. Clinics in perinatology, 31(3), 501-528.
[33] Rajabi, M., Signorelli, P., Gorincioi, E., Ghidoni, R., & Santaniello, E. (2010). Antiproliferative activity of N 6-isopentenyladenosine on MCF-7 breast cancer cells: cell cycle analysis and DNA-binding study. DNA and cell biology, 29(11), 687-691.
[34] Sahoo, S. K., & Labhasetwar, V. (2003). Nanotech approaches to drug delivery and imaging. Drug discovery today, 8(24), 1112-1120.
[35] Smith, D. J. (2007). Characterization of nanomaterials using transmission electron microscopy. The Royal Society of Chemistry: Cambridge.1-27.
[36] Angeli, E., Buzio, R., Firpo, G., Magrassi, R., Mussi, V., Repetto, L., & Valbusa, U. (2008). Nanotechnology applications in medicine. Tumori Journal, 94(2), 206-215.
[37] Rajabi, M., Srinivasan, M., & Mousa, S. A. (2016). Nanobiomaterials in drug delivery. In Nanobiomaterials in Drug Delivery. William Andrew Publishing. 1-37.
[38] Allen, T. M., & Martin, F. J. (2004, December). Advantages of liposomal delivery systems for anthracyclines. In Seminars in oncology. WB Saunders. (31), 5-15.
[39] Bhattacharyya, P., Pradhan, K., Paul, S., & Das, A. R. (2012). Nano crystalline ZnO catalyzed one pot multicomponent reaction for an easy access of fully decorated 4H-pyran scaffolds and its rearrangement to 2-pyridone nucleus in aqueous media. Tetrahedron Letters, 53(35), 4687-4691.
[40] Heravi, M. M., Oskooie, H. A., Karimi, N., & Hamidi, H. (2011). KAl (SO4) 2• 12H2O catalyzed efficient synthesis of 3, 4, 6-trisubstituted 2-pyridone in water. Chinese Chemical Letters, 22(9), 1059-1062.
[41] Louis, H., Fidelis, G. K., Fidelis, T. T., & Onoshe, S. (2019). Curcumin and Curcumin-based derivatives as anti-cancer agents: Recent Nano-Synthetic Methodologies and Anti-cancer Therapeutic Mechanisms. Journal of Medicinal and Chemical Sciences, 2(41-75.), 59-63.
[42] Freitas Jr, R. A. (2000). Nanodentistry. The Journal of the American Dental Association, 131(11), 1559-1565.
[43] Yao, J., Yang, M., & Duan, Y. (2014). Chemistry, biology, and medicine of fluorescent nanomaterials and related systems: new insights into biosensing, bioimaging, genomics, diagnostics, and therapy. Chemical reviews, 114(12), 6130-6178.
[44] Shan, J., & Tenhu, H. (2007). Recent advances in polymer protected gold nanoparticles: synthesis, properties and applications. Chemical Communications, (44), 4580-4598.
[45] Cai, W., Gao, T., Hong, H., & Sun, J. (2008). Applications of gold nanoparticles in cancer nanotechnology. Nanotechnology, science and applications, 1, 17.
[46] De Jong, W. H., & Borm, P. J. (2008). Drug delivery and nanoparticles: applications and hazards. International journal of nanomedicine, 3(2), 133.
[47] Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., & Medintz, I. L. (2013). Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. Chemical reviews, 113(3), 1904-2074.
[48] Gao, J., Huang, X., Liu, H., Zan, F., & Ren, J. (2012). Colloidal stability of gold nanoparticles modified with thiol compounds: bioconjugation and application in cancer cell imaging. Langmuir, 28(9), 4464-4471.
[49] Alexis, F., Rhee, J. W., Richie, J. P., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008, January). New frontiers in nanotechnology for cancer treatment. In Urologic Oncology: Seminars and Original Investigations. Elsevier. 26(1), 74-85.
[50] Loos, M. (2014). Carbon nanotube reinforced composites: CNT Polymer Science and Technology. Elsevier.
[51] Ju-Nam, Y and Lead, J. (2016). Properties, Sources, Pathways, and Fate of Nanoparticles in the Environment. Engineered Nanoparticles and the Environment: Biophysicochemical Processes and Toxicity. 39-117.
[52] Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010). Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced drug delivery reviews, 62(3), 346-361.
[53] Zhao, Y., Gu, X., Ma, H., He, X., Liu, M., & Ding, Y. (2011). Association of glutathione level and cytotoxicity of gold nanoparticles in lung cancer cells. The Journal of Physical Chemistry C, 115(26), 12797-12802.
[54] Medley, C. D., Smith, J. E., Tang, Z., Wu, Y., Bamrungsap, S., & Tan, W. (2008). Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Analytical chemistry, 80(4), 1067-1072.
[55] Cheng, Y., Samia, A. C., Meyers, J. D., Panagopoulos, I., Fei, B., & Burda, C. (2008). Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. Journal of the American Chemical Society, 130(32), 10643-10647.
[56] Piller, C. (2006). Science’s tiny, big unknown. Los Angeles Times, 1, A1.
[57] Morgan, K. (2005). Development of a preliminary framework for informing the risk analysis and risk management of nanoparticles. Risk Analysis: An International Journal, 25(6), 1621-1635.
[58] Borm, P., Klaessig, F. C., Landry, T. D., Moudgil, B., Pauluhn, J., Thomas, K., & Wood, S. (2006). Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicological Sciences, 90(1), 23-32.
[59] Balshaw, D. M., Philbert, M., & Suk, W. A. (2005). Research strategies for safety evaluation of nanomaterials, Part III: nanoscale technologies for assessing risk and improving public health. Toxicological Sciences, 88(2), 298-306.
[60] Thomas, T., Thomas, K., Sadrieh, N., Savage, N., Adair, P., & Bronaugh, R. (2006). Research strategies for safety evaluation of nanomaterials, part VII: evaluating consumer exposure to nanoscale materials. Toxicological Sciences, 91(1), 14-19.
[61] Hameed, A., Fatima, G. R., Malik, K., Muqadas, A., & Fazal-ur-Rehman, M. (2018). Scope of Nanotechnology in Cosmetics: Dermatology and Skin Care Products. Journal of Medicinal and Chemical Sciences, 2(1), 9-16.
[62] Love, S. A., Maurer-Jones, M. A., Thompson, J. W., Lin, Y. S., & Haynes, C. L. (2012). Assessing nanoparticle toxicity. Annual review of analytical chemistry, 5, 181-205.
[63] Lee, S. Y., & Cheng, J. X. (2010). Clearance of nanoparticles during circulation. Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing, 1-32.
[64] Johnston, H. J., Semmler-Behnke, M., Brown, D. M., Kreyling, W., Tran, L., & Stone, V. (2010). Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicology and applied pharmacology, 242(1), 66-78.